Lee's Pharmaceutical Holdings Ltd, a research-driven biopharmaceutical company based in the Cayman Islands, has over 20 years of experience in China's pharmaceutical industry. With solid infrastructures in drug development, clinical development, regulatory affairs, manufacturing, and sales, the company operates globally and currently markets 14 products in China. Their portfolio includes cardiovascular, infectious diseases, dermatology, oncology, gynecology, ophthalmology, and other therapeutic areas. Lee's Pharm has over 30 products in different development stages, resulting from internal R&D and acquisitions of licensing and distribution rights from international companies. Recognized for its success, Lee's Pharm ranked as the second-best small-cap company in China and was selected as one of Asia's 200 Best Under A Billion Companies by Forbes.